Long-term effects of spironolactone in peritoneal dialysis patients
about
Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain.Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues.ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II - Management of Various Cardiovascular Complications.Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled TrialSpironolactone Effect in Hepatic Ischemia/Reperfusion Injury in Wistar RatsManagement of hyperkalaemia in chronic kidney disease.Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.Preserving the peritoneal membrane in long-term peritoneal dialysis patients.Pharmacotherapy of Hypertension in Chronic Dialysis Patients.Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.Potassium supplementation and long-term outcomes in chronic peritoneal dialysis patients with end-stage renal disease: a propensity score matching study.Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients.
P2860
Q30235413-25BB363D-1724-446F-AD7F-F752AB9CEDACQ31004378-10152CB4-AE3E-4AC9-8ACC-60E943ECD263Q35904403-E864BBB9-C08D-4AD1-8199-8B532BE7AA73Q35992464-C8EF104B-0911-4B26-8DC4-50AFCF9C1678Q36025666-D2215B3E-93CA-4986-B7F2-F1DC20A3F86FQ36427277-B0C13DA4-EDB4-48B1-9779-411F400D6854Q38249892-F76CA02F-B260-41D7-AEAA-B6D5B5B557EEQ38560705-A35ACF52-6324-495F-8B13-DD00E2E3CA0FQ38568149-E02514F8-73B6-4DC3-AC15-296EF5F31056Q38802032-CE8720C2-E37E-4778-8552-91439897EB7BQ38815486-8DA34B21-8F60-41B8-8F33-F11CE990279DQ38837657-1D9D7958-C7D1-4205-9882-4A786F938A57Q40521456-B4844F74-5D12-4E48-BA83-2DDEAD7FEEDDQ41877664-1849128C-FCFC-4E7D-B9AA-937E00395BA2Q47134104-EC82ED30-BBAD-4327-A734-3B76FCB72FE2
P2860
Long-term effects of spironolactone in peritoneal dialysis patients
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Long-term effects of spironolactone in peritoneal dialysis patients
@ast
Long-term effects of spironolactone in peritoneal dialysis patients
@en
type
label
Long-term effects of spironolactone in peritoneal dialysis patients
@ast
Long-term effects of spironolactone in peritoneal dialysis patients
@en
prefLabel
Long-term effects of spironolactone in peritoneal dialysis patients
@ast
Long-term effects of spironolactone in peritoneal dialysis patients
@en
P2093
P2860
P356
P1476
Long-term effects of spironolactone in peritoneal dialysis patients
@en
P2093
Hirofumi Tamai
Hiroshige Ohashi
Masanobu Horie
Masashi Mizuno
Nagoya Spiro Study Group
Seiichi Matsuo
Shoichi Maruyama
Takeyuki Hiramatsu
Tatsuaki Matsubara
P2860
P304
P356
10.1681/ASN.2013030273
P577
2013-12-12T00:00:00Z